Document:

DAL Group, LLC

950 S. Pine Island Road

Plantation, FL 33324

Telephone: 305.776.8618

 

 

February 16, 2012

 

 

VIA ELECTRONIC MAIL 

 

	
        Law Offices of David J. Stern, P.A., and

        David J. Stern

        c/o Jeffrey Tew, Esq.

        Tew Cardenas LLP

        1441 Brickell Avenue, 15th Floor

        Miami, FL 33131-3407

         

         
	
        BA Note Acquisition, LLC

        c/o Jay M. Sakalo Esq.

        Bilzin Sumberg Baena Price and Axelrod LLP

        1450 Brickell Avenue, Suite 2300

        Miami, FL 33131-3456

         

 

Gentlemen:

 

Reference is made to the
Forbearance Agreement made and entered into as of the 30th day of December, 2011, by and among BA Note Acquisition,
LLC, a Delaware limited liability company (“BA Note”), DAL Group, LLC, a Delaware limited liability company
(“Borrower”), DJS Processing, LLC, a Delaware limited liability company (“DJS Processing;” and together
with BA Note, the “Lenders”), and Law Offices of David J. Stern, P.A., a Florida professional corporation (“Law
Office”) (the "Third Forbearance Agreement"). Capitalized terms used, but not defined in this Letter
Agreement, shall have the meanings set forth in the Third Forbearance Agreement

 

By their signatures below,
the Parties agree to amend the Forbearance Agreement in the manner set forth in this Letter Agreement:

 

3.2The second paragraph of the Assignment
shall be modified as follows:

 

For good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Assignor hereby, absolutely and not as collateral, assigns, transfers,
sets over and conveys to the Assignees, all of Assignor's right, title and interest in and to the proceeds from the Collection
Cases, after payment of (a) attorneys' fees and costs related to the Collection Cases and (b) a consulting fee to David J. Stern
equal to 10% of the gross proceeds received by Assignor from the Collection Cases, less the Operating Expense Deduction (as defined
below) (such remainder, the "Net Proceeds"). For purposes of this Assignment, Operating Expense Deduction shall
mean fifty percent (50%) of Assignor's operating expenses funded by DJS Processing or Lender from and after the Third Forbearance
Date. The Operating Expense Deduction shall be capped at a maximum of $400,000. Any Net Proceeds not remitted to DJS Processing
or Lender and retained by Law Office, shall be considered funded by DJS Processing for purposes of calculating the Operating Expense
Deduction. Notwithstanding the foregoing, the Parties acknowledge and agree that, except as provided in Section 4.10, neither DJS
Processing nor Lender shall have any obligation to fund the operating expenses of Assignor.

    	 

    	 	

    
  

Article 3 of the Third Forbearance Agreement
is amended to add the following:

 

3.4Contingency Fee Agreement.
Law Office represents that it has executed an Amended Contingency Fee Agreement and Authority to Represent dated as of January
25, 2012 (the “Amended Contingency Fee Agreement”) with Tew Cardenas LLP. Law Office shall not modify the terms
of the Amended Contingency Fee Agreement without the prior written consent of DJS Processing, and, for so long as the Indebtedness
remains outstanding, Lender, which consent shall not be unreasonably withheld. This Article 3.4 shall survive the repayment of
the Indebtedness.

 

Section 4.7 of the Third Forbearance Agreement
shall be modified as follows:

 

By February 29, 2012, (a) Borrower,
DJS Processing and each Guarantor shall enter into control account agreements acceptable to Lender that grant control to Lender
over all of their operating accounts in connection with the occurrence of a Termination Event and (b) Law Office shall enter into
control account agreements acceptable to Lender that grant control to Lender over all of Law Office's operating accounts in connection
with the occurrence of a Termination Event. Borrower and DJS Processing shall not, and shall cause Guarantor not to, open and/or
maintain any deposit accounts other than the Existing Bank Accounts.

 

Article 4 of the Third Forbearance Agreement
is amended to add the following:

 

4.10Payroll. No
later than February 17, 2012, Borrower shall fund, from its current cash on hand, the past due payroll of Law Office through February
10, 2012, in an amount not to exceed the amount set forth on the Law Office budget attached as Exhibit B (the "Law Office
Budget"), and deliver to Law Office $28,044.97 that may be used by Law Office to fund only those expenses set forth in
the Law Office Budget. Thereafter, Borrower may, but shall not be obligated, to fund payroll or any other operating expense of
Law Office through the Forbearance Expiration Date. Notwithstanding the foregoing, if Borrower funds the payroll or other operating
expenses of Law Office from funds borrowed from Lender, such amount shall constitute Indebtedness.

 

The
Borrower Parties and Law Office certify to Lender that all acknowledgements, representations and warranties of such Borrower Parties
and Law Office contained in the Third Forbearance Agreement are true and correct as of the date of this Letter Agreement and, except
as modified by this Letter Agreement, the terms of the Third Forbearance Agreement shall remain in full force and effect.

 

    	2

    	 

    

 

By their signatures below, each of the undersigned
parties acknowledges and agrees to the terms of this Letter Agreement.

 

	 	 	Very truly yours, 	 
	 	 	 	 
	 	 	/s/ Stephen J. Bernstein 	 
	 	 	 	 
	 	 	 Stephen J. Bernstein 	 

 

	ACCEPTED AND AGREED BY:	 	
	 
	BA NOTE ACQUISITION, LLC, 
	 	LAW OFFICES OF DAVID J. STERN, P.A.,
    	 
	a Delaware limited liability company 	 	a Florida professional
        corporation  	 
	 	 	 			 
	By: 	DMRJ Group I, LLC, its manager 	 	By:	/s/ David J. Stern  	 
	 	 	 	Name:  	David J. Stern  	 
	By:  	/s/ David Levy	 	Title: 	President	 
	Name: 	David Levy  	 	 	 	 
	Title: 	 	 	 	 	 

 

 

	DAL GROUP, LLC, 
	 	 	DJS PROCESSING, LLC,	 
	a Delaware limited liability company 	 	 	a Delaware limited liability company	 
	 	 	 	 	 	 
	By: 	/s/ Stephen J. Bernstein  	 	By: 	/s/ Stephen J. Bernstein	 
	Name: 	Stephen J. Bernstein  	 	Name: 	Stephen J. Bernstein 	 
	Title:  	President 	 	Title: 	President 	 

 

 

	PROFESSIONAL TITLE AND ABSTRACT
    COMPANY OF FLORIDA, LLC	 	 	DEFAULT SERVICING, LLC	 
	 	 	 	 	 	 
	By: 	/s/ Stephen J. Bernstein  	 	By: 	/s/ Stephen J. Bernstein	 
	Name: 	Stephen J. Bernstein  	 	Name: 	Stephen J. Bernstein 	 
	Title:  	President 	 	Title: 	President 	 

 

    	3IN THE CIRCUIT COURT OF THE 11TH JUDICIAL CIRCUIT, IN AND FOR MIAMI-DADE COUNTY, FLORIDA
	 	 
	 	GENERAL JURISDICTION DIVISION
	 	 
	 	CASE NO. 12-05495 CA 06

 

SOCIUS CG II, LTD., a Bermuda

exempted company,

 

Plaintiff,

 

v.

 

BIONOVO, INC.,

a Delaware corporation,

 

Defendant.

_________________________________________/

 

AGREED ORDER GRANTING JOINT EXPEDITED 

MOTION FOR ORDER APPROVING SETTLEMENT
OF CLAIM

 

THIS CAUSE came
before the Court for hearing on February 16, 2012, on the Joint Expedited Motion for Order Approving Stipulation for Settlement
of Claim (the “Motion”) filed by Plaintiff, Socius CG II, Ltd. (“Socius”), and Defendant, Bionovo, Inc.
(“Bionovo”). The Court, having reviewed the Motion and other pertinent portions of the record, noting the Stipulation
for Settlement of Claim reflecting the agreement of the parties (the “Stipulation”), having heard argument of counsel,
and being otherwise duly advised in the premises, it is hereby

 

ORDERED AND ADJUDGED
that the Motion is GRANTED as follows:

 

1.          The
Court approves the Stipulation and finds that terms and conditions of the issuance to Socius of 2,500,000 shares of common stock
of Bionovo (“Common Stock”) in exchange for the settlement of Socius’s claim against Bionovo in the amount of
$250,000 are fair, reasonable and adequate.

 

    	 

    	 

    

 

CASE NO.: 12-05495
CA 06

 

2.          Accordingly,
the Common Stock shall constitute exempted securities under Section 3(a)(10) of the Securities Act of 1933.

 

3.          The
parties shall fully comply with all terms and conditions of the Stipulation, which are incorporated herein by this reference.

 

4.          This
action is therefore DISMISSED WITH PREJUDICE. The Court retains jurisdiction for purposes of enforcing the Stipulation.

 

DONE AND ORDERED
in Chambers at Miami, Miami-Dade County, Florida, this 16th day of February, 2012.

 

	 	/s/ David C. Miller	 
	 	CIRCUIT COURT JUDGE

Copies furnished to:

Adam B. Leichtling, Esq.

Mark A. Salky, Esq.

 

    	2IN THE CIRCUIT COURT OF THE 11TH  JUDICIAL CIRCUIT, IN AND FOR MIAMI-DADE COUNTY, FLORIDA
	 	 
	 	GENERAL JURISDICTION DIVISION
	 	 
	 	CASE NO. 12-05495 CA 06

 

SOCIUS CG II, LTD., a Bermuda

exempted company,

 

Plaintiff,

 

v.

 

BIONOVO, INC.,

a Delaware corporation,

 

Defendant.

_________________________________________/

 

STIPULATION FOR SETTLEMENT OF CLAIM

 

Plaintiff, Socius CG II,
Ltd. (“Socius”), on the one hand, and Defendant, Bionovo, Inc. (“Bionovo”),
on the other hand, stipulate to the entry of the Agreed Order Approving Settlement (the “Agreed Order”), attached hereto
as Exhibit A, and further stipulate and agree as follows:

 

1.          Socius
and Bionovo request that the Court enter an order substantially in the form of the Agreed Order attached hereto as Exhibit A.

 

2.          Bionovo
is a Delaware corporation with its principal place of business in Emeryville, California 94608.

 

3.          Socius
owns a bona fide claim against Bionovo in the amount of $250,000 (the “Claim”). The Claim represents a non-refundable
fee owed to Socius pursuant to the Securities Purchase Agreement, dated December 31, 2012, by and between Bionovo and Socius for
Soicius’s commitment to purchase a certain amount of shares of Series A preferred stock of Bionovo as set forth therein.
Such fee is past due in its entirety.

 

    	 

    	 

    

 

CASE NO.: 12-05495
CA 06

 

4.          Bionovo
has not paid, and will not be able to pay in the near term, any amount due on the Claim. As a result, on February 13, 2012, Socius
filed the above-captioned action (the “Action”), which Action the parties now seek to settle by this Stipulation.

 

5.          Bionovo
desires to settle the Claim in exchange for the issuance to Socius of shares of Bionovo’s common stock (the “Common
Stock”). Socius is willing to accept such shares of Common Stock in accordance with the terms of this Stipulation, subject
to court approval following a hearing as required by Section 3(a)(10) of the Securities Act of 1933, as amended (the “Act”).
Section 3(a)(10) provides in its entirety as follows:

 

Section 3 — Classes of Securities
under this Title

 

		(a)	Exempted securities. Except as hereinafter expressly provided, the provisions of this title shall
not apply to any of the following classes of securities:...

 

		10.	Except with respect to a security exchanged in a case under title 11 of the United States Code,
any security which is issued in exchange for one or more bona fide outstanding securities, claims or property interests,
or partly in such exchange and partly for cash, where the terms and conditions of such issuance and exchange are approved, after
a hearing upon the fairness of such terms and conditions at which all persons to whom it is proposed to issue securities in
such exchange shall have the right to appear, by any court, or by any official or agency of the United States, or by any
State or Territorial banking or insurance commission or other governmental authority expressly authorized by law to grant such
approval;

 

(Emphasis added.)

 

6.          Socius
is the sole person to whom the shares of Common Stock are proposed to be issued, and is therefore the only person entitled to notice
of hearing and an opportunity to be heard in accordance with the statute. Socius has agreed to the proposed settlement terms and
conditions, and believes that they are sufficiently fair such that Socius is willing to enter into this Stipulation. In addition,
Bionovo’s board of directors has considered the proposed settlement and has resolved that its terms and conditions are fair
to, and in the best interests of, Bionovo and its stockholders. Accordingly, both parties shall request Court approval of the settlement
provided for herein (following the hearing referred to in the next sentence) as fair, reasonable and adequate. The parties shall
submit this Stipulation to the Court, on a motion seeking an expedited hearing, and shall request that the Court enter the Agreed
Order approving this Stipulation at the hearing thereon.

 

    	2

    	 

    

 

CASE NO.: 12-05495
CA 06

 

7.          It
is the intent and effect of this Stipulation that the Agreed Order, when signed, shall end, finally and forever (i) any claims
to payment or compensation of any kind or nature that Socius had, now has, or may assert in the future against Bionovo arising
out of the Claim, and (ii) any claims, including, without limitation, for offset or counterclaim, that Bionovo had, now has, or
may assert in the future against Socius arising out of the Claim. In this regard, and subject to full and complete compliance with
the Agreed Order, effective upon the execution of the Agreed Order, each party hereby releases and forever discharges the other
party, including all of the other party’s employees, officers, directors, members, partners, agents, affiliates, subsidiaries
and attorneys, from any and all claims, demands, obligations (fiduciary or otherwise), and causes of action, whether known or unknown,
suspected or unsuspected, arising out of, connected with, or incidental to the Claim. Each party further agrees that with respect
to the matters released herein, such party expressly waives any and all rights and benefits conferred upon it by the provisions
of California Civil Code Section 1542 and any similar law of any state or territory of the United States. California Civil Code
Section 1542 provides, in full, as follows:

 

§ 1542 General Release-Claims
Extinguished. A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor
at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the
debtor.

 

    	3

    	 

    

 

CASE NO.: 12-05495
CA 06

 

8.          In
full and final settlement of the Claim, Bionovo will issue and deliver to Socius or its designee 2,500,000 shares of Common Stock
for the Claim (collectively, the “Settlement Shares”). Further, such shares will be subject to adjustment as described
in paragraph 10 below to reflect the intention of the parties that the total number of shares issued be based upon an average trading
price of the Common Stock for a specified period of time prior and subsequent to entry of the Agreed Order. Under no circumstance
whatsoever may the number of Settlement Shares issued to Socius or its designee, aggregated with all shares of Common Stock then
owned or beneficially owned or controlled by, collectively, Socius and its affiliates, at any time exceed 9.9% of the total number
of shares of Common Stock then outstanding.

 

9.          No
later than the first trading day following the date that the Court enters its Agreed Order approving this Stipulation, Bionovo
shall: (i) immediately issue the number of shares of Common Stock required by paragraph 8 above to Socius’s or its designee’s
balance account with The Depository Trust Company (DTC) through the Fast Automated Securities Transfer (FAST) Program of DTC’s
Deposit/Withdrawal Agent Commission (DWAC) system, without any restriction on transfer or resale, time being of the essence, by
transmitting via facsimile and overnight delivery such irrevocable and unconditional instruction to Bionovo’s stock transfer
agent, and (ii) if required by Bionovo’s stock transfer agent cause its legal counsel to issue an opinion to Bionovo’s
transfer agent, in form and substance acceptable to both parties and such transfer agent, that the shares may be so issued (such
issuance, the “Initial DWAC Issuance,” and the date upon which such issuance is complete, the “Initial DWAC Issuance
Date”).

 

    	4

    	 

    

 

CASE NO.: 12-05495
CA 06

 

10.          The
total number of shares of Common Stock to be issued to Socius or its designee in connection with this Stipulation and the Agreed
Order shall be adjusted on the 21st trading day following the Initial DWAC Issuance Date (the 20 trading day period following the
Initial DWAC Issuance Date, the “ True-Up Period,” and the 21st trading day following the Initial DWAC Issuance Date,
the “True-Up Date”), as follows: (i) if the number of “VWAP Shares” (as defined below) exceeds the number
of Settlement Shares initially issued, then Bionovo will issue and deliver to Socius or its designee, as DWAC shares, additional
shares of Common Stock equal to the difference between (x) the total number of VWAP Shares and (y) the number of Settlement Shares,
and (ii) if the number of VWAP Shares is less than the number of Settlement Shares, then Socius or its designee will return to
Bionovo for cancellation that number of shares equal to the difference between (x) the total number of VWAP Shares and (y) the
number of Settlement Shares issued in the Initial DWAC Issuance.

 

a.       The number of VWAP
Shares shall be equal to (i) $250,000 divided by 70% of the trading volume weighted average price as reported by Bloomberg LP (the
“VWAP”) of the Common Stock over True-Up Period, plus (ii) Socius’s legal fees, expenses and costs incurred through
the True-Up Date, with the total dollar amount divided by the VWAP of the Common Stock over the True-Up Period.

 

b.       If, at any time during
the True-Up Period, the trading price of the Common Stock declines by 15% or more from the trading price on the Initial DWAC Issuance
date, Socius may deliver a written notice to Bionovo by facsimile or email requesting that a specified number of additional shares
of Common Stock be delivered and containing the calculation for the number of additional shares requested. Socius may in its sole
discretion deliver one or more such notices during the True-Up Period. Within one trading day following delivery of each such notice,
Bionovo shall deliver to Socius or its designee, in compliance with the procedure set forth in paragraph 10 above (including, without
limitation, issuance of the legal opinion to the transfer agent at Bionovo’s sole cost and expense), the number of additional
shares of Common Stock requested in the notice. Any additional shares of Common Stock issued or issuable pursuant to this Section
10.b. will be considered Settlement Shares for purposes of any calculation of the total number of shares to be issued by, or returned
to, Bionovo pursuant to the first paragraph of this Section 10.

 

    	5

    	 

    

 

CASE NO.: 12-05495
CA 06

 

c.       In no event shall
the number of shares of Common Stock issued to Socius or its designee in connection with the settlement of the Claim, aggregated
with all shares of Common Stock then owned or beneficially owned or controlled by, collectively, Socius and its affiliates, at
any time exceed 9.9% of the total number of shares of Common Stock then outstanding.

 

11.          The
Parties hereby make the following representations and warranties:

 

a.    Bionovo represents
and warrants to Socius and its affiliates that the shares of Common Stock provided for above are duly authorized and, when issued
pursuant to the Agreed Order, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens, encumbrances
and preemptive and similar rights to subscribe for or purchase securities. Bionovo has reserved from its duly authorized capital
stock a number of shares of Common Stock at least equal to the number of shares that could be issued pursuant to the terms of this
Stipulation. Without limitation, Bionovo hereby waives any provision in any agreement related to the debt comprising the Claim
(x) requiring payments to be applied in a certain order, manner, or fashion, or (y) providing for exclusive jurisdiction in any
court other than this Court. Bionovo further represents that it has all necessary power and authority to execute, deliver and perform
all of its obligations under this Stipulation. The execution, delivery and performance of this Stipulation by Bionovo has been
duly authorized by all requisite action on the part of Bionovo and this Stipulation has been duly executed and delivered by Bionovo.

 

    	6

    	 

    

 

CASE NO.: 12-05495
CA 06

 

b.    Socius represents
and warrants to Bionovo that, as of the date of this Stipulation and during the 90 calendar days prior to the date of this Stipulation,
neither Socius nor any affiliate thereof is or was an officer, director, or 10% or more stockholder of Bionovo.

 

12.          For
so long as Socius or any of its affiliates holds any shares of Common Stock of Bionovo, neither Socius nor any of its affiliates
will: (i) vote any shares of Common Stock owned or controlled by it, or solicit any proxies or seek to advise or influence any
person with respect to any voting securities of Bionovo; or (ii) engage or participate in any actions, plans or proposals that
relate to or would result in (a) Socius or any of its affiliates acquiring additional securities of Bionovo, alone or together
with any other person, which would result in Socius and its affiliates collectively beneficially owning or controlling, or being
deemed to beneficially own or control, more than 9.9% of the total outstanding Common Stock or other voting securities of Bionovo,
(b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Bionovo or any of its subsidiaries,
(c) a sale or transfer of a material amount of assets of Bionovo or any of its subsidiaries, (d) any change in the present board
of directors or management of Bionovo, including any plans or proposals to change the number or term of directors or to fill any
existing vacancies on the board, (e) any material change in the present capitalization or dividend policy of Bionovo, (f) any other
material change in Bionovo’s business or corporate structure, (g) changes in Bionovo’s charter, bylaws or instruments
corresponding thereto or other actions which may impede the acquisition of control of Bionovo by any person, (h) causing a class
of securities of Bionovo to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer
quotation system of a registered national securities association, (i) causing a class of equity securities of Bionovo to become
eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934 (the “Exchange
Act”), or (j) taking any action, intention, plan or arrangement similar to any of those enumerated above. The provisions
of this paragraph may not be modified or waived without further order of the Court.

 

    	7

    	 

    

 

CASE NO.: 12-05495
CA 06

 

13.         The
parties agree that, for the period of 180 days from True-Up Date, and regardless of whether Socius or its affiliates then hold
any debt or equity securities of Bionovo, Socius and its affiliates shall have the exclusive right to enter into transactions with
Bionovo whereby Bionovo directly or indirectly issues Common Stock or Common Stock equivalents to a party in exchange for outstanding
securities, claims or property interests, or partly in such exchange and partly for cash, in one or more transactions carried out
pursuant to Section 3(a)(9) or Section 3(a)(10) of the Act.

 

14.         On
the first trading day after the date of the Agreed Order, and prior to the opening time for trading stocks on public exchanges
located in New York City, Bionovo shall file a Form 8-K Report pursuant to Section 13 or Section 15(d) of the Exchange Act disclosing
the issuance of shares pursuant to the Agreed Order approving this Stipulation and attaching a copy of the Agreed Order and this
Stipulation as an exhibit thereto.

 

15.         Bionovo
hereby agrees to indemnify, defend and hold Socius and its affiliates harmless with respect to all obligations of Bionovo arising
from or incident or related to this Stipulation, including, without limitation, any claims or actions brought by shareholders of
Bionovo related to this Stipulation.

 

16.         The
parties to this Stipulation represent that each of them has been advised as to the terms and legal effect of this Stipulation and
the Agreed Order provided for herein, and that the settlement and compromise stated herein is final and conclusive forthwith, subject
to the conditions stated herein, and each attorney represents that his or her client has freely consented to and authorized this
Stipulation.

 

    	8

    	 

    

 

CASE NO.: 12-05495
CA 06

 

17.         Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in Miami-Dade County, Florida,
for the adjudication of the above-captioned action and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court or that such suit, action or proceeding
is improper or inconvenient venue for such proceeding.

 

18.         Upon
entry of the Agreed Order approving this Stipulation, the Action shall be dismissed with prejudice. The Court shall retain jurisdiction
to enforce the terms of this Stipulation.

 

19.         This
Stipulation constitutes Bionovo’s answer to the Complaint in this Action. Each party hereto waives a statement of decision,
and the right to appeal from the Order after its entry. Bionovo further waives any defense based on the rule against splitting
causes of action. Except as expressly set forth herein, each party shall bear its own attorneys’ fees, expenses and costs.

 

20.         This
Stipulation may be executed in counterparts and by facsimile, pdf or other electronic format, each of which shall constitute an
original and all of which together shall be deemed together as a single document.

 

[Signature Pages to
Follow]

 

    	9

    	 

    

 

CASE NO.: 12-05495
CA 06

 

	DATED: February 15, 2012	LAPIN & LEICHTLING, LLP
	 	Attorneys for Plaintiff, Socius CG II, Ltd.
	 	255 Alhambra Circle, Suite 1250
	 	Coral Gables, Florida 33134
	 	Telephone: (305) 569-4100
	 	Facsimile:  (305) 569-0000
	 	E-mail: aleichtling@LL-lawfirm.com
	 	 
	 	By:	/s/ Adam B. Leichtling
	 	 	     ADAM B. LEICHTLING
	 	 	     Florida Bar No.
	 	 
	DATED: February 15, 2012	SOCIUS CG II, LTD.
	 	 
	 	By:	/s/ Terren Peizer
	 	 	     Terren Peizer
	 	 	     Managing Director
	 	 	     Socius CG II, Ltd.
	 	 
	DATED: February 15, 2012	GREENBERG TRAURIG, P.A.
	 	Attorneys for Defendant Bionovo, Inc.
	 	333 Avenue of the Americas
	 	Miami, Florida 33131
	 	Telephone: (305) 579-0500
	 	Facsimile:  (305) 579-0717
	 	E-mail: salkym@gtlaw.com
	 	 
	 	By:	/s/ Mark A. Salky
	 	 	     MARK A. SALKY
	 	 	     Florida Bar No. 058221
	 	 
	DATED: February 15, 2012	BIONOVO, INC.
	 	 
	 	By:	/s/ David Boyle
	 	 	     David Boyle
	 	 	     Chief Financial Officer
	 	 	     Bionovo, Inc.

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]